News Photo

BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024

Bold Therapeutics announces that Dr. Do-Youn Oh’s group at Seoul National University College of Medicine will present at the AACR Meeting, April 5-10, 2024.

Read more
Post Photo

01-23-2024

Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024

Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024.
Post Photo

09-22-2023

Bold Therapeutics Selected as a 2023 Company to Watch by Life Sciences British Columbia (LSBC)

Bold Therapeutics Selected as a 2023 Company to Watch by Life Sciences British Columbia (LSBC).
Post Photo

06-07-2023

Bold Therapeutics Presents Positive Interim Phase 2 Results for BOLD-100 in Advanced Gastric and Biliary Tract Cancer at ASCO 2023

Bold Therapeutics announced positive interim results in advanced gastric and biliary tract cancer at the 2023 ASCO Annual Meeting.
Post Photo

06-01-2023

Bold Therapeutics to Present Positive Interim Gastric and Biliary Tract Cancer Results at ASCO 2023 Annual Meeting

Bold Therapeutics will be presenting positive interim results in advanced gastric and biliary tract cancer at 2023 (ASCO) Annual Meeting on June 2-6.
Post Photo

04-18-2023

Bold Therapeutics Presents Jaw-Dropping Interim Phase 2 Clinical Data for BOLD-100 in the Treatment of Advanced Colorectal Cancer at AACR 2023

Bold Therapeutics is excited to share interim Phase 2 data for BOLD-100 in the treatment of advanced colorectal cancer.
Post Photo

04-13-2023

Bold Therapeutics to Present Best-in-Class Phase 2 Metastatic Colorectal Cancer Data at AACR 2023

Bold Therapeutics is excited to present robustly positive interim Phase 2 data in metastatic colorectal cancer at the upcoming AACR conference.
Post Photo

04-13-2023

Bold Therapeutics to Present Best-in-Class Phase 2 Metastatic Colorectal Cancer Data at AACR 2023

Bold Therapeutics is excited to present robustly positive interim Phase 2 data in metastatic colorectal cancer at the upcoming AACR conference.
Post Photo

10-14-2022

Bold Therapeutics Attending and Presenting at the BIO-Europe 2022 and BIO-Europe 2022 Virtual Conferences

Bold Therapeutics announces that they will be attending and presenting at BIO-Europe 2022 and BIO-Europe 2022 Virtual Conferences.
Post Photo

06-27-2022

Bold Therapeutics BOLD-100 Early mCRC Data to be Showcased at 2022 Metals in Medicine Gordon Research Conference

Bold Therapeutics is excited to share compelling early efficacy data on BOLD-100 at the 2022 Metals in Medicine Gordon Research Conference.
Post Photo

05-10-2022

Bold Therapeutics to Present at Bio Korea 2022 as part of the Canadian Trade Delegation

Bold Therapeutics is pleased to have been invited to present at Bio Korea 2022 as part of the Canadian trade delegation.
Post Photo

04-06-2022

BOLD-100s Broad Potential Featured at the AACR Annual Meeting 2022

Bold Therapeutics announced that it will present research supporting the use of BOLD-100 at the AACR Annual Meeting 2022 on April 8-13, 2022 in New Orleans.
Post Photo

04-04-2022

Bold Therapeutics Selected as 2nd Place Winner at 2022 Innovator Pitch Challenge

Bold Therapeutics is excited to announce second place in the Innovator’s Pitch Challenge at the Digital Redefining Early-Stage Investments Conference.
Post Photo

03-10-2022

Bold Therapeutics Successfully Completes Phase 1b Trial and Advances into Global Phase 2 Trial of BOLD-100 in the Treatment of Advanced GI Cancers

Bold Therapeutics successfully completed Phase 1b of its oncology trial of BOLD-100 combined with FOLFOX in the treatment of advanced gastrointestinal cancers.
Post Photo

01-13-2022

Bold Therapeutics and Hana Pharm Extend Option Agreement for BOLD-100, a First-in-Class Anti-Resistance Therapeutic

Bold Therapeutics announces an extension of the option agreement with Hana Pharm for development and commercialization rights to BOLD-100 in South Korea.
Post Photo

09-16-2021

BOLD-100 Exhibits Potent Anti-Tumor Activity in Validated I/O In Vivo Models

Bold Therapeutics has demonstrated potent anti-tumor activity in combination with a PD-1 checkpoint inhibitor in an in vivo model of colorectal cancer.
Post Photo

07-07-2021

Bold Therapeutics Receives FDA Clearance to Add U.S. Sites for Phase 1b / 2a Trial of BOLD-100 in the Treatment of Advanced GI Cancers

Bold Therapeutics announces the addition of U.S. Sites for its phase 1b / 2a trial of BOLD-100 in the treatment of advanced GI cancers.
Post Photo

06-23-2021

Bold Therapeutics Collaborates with Dr. Stephen Barr at Western University to Study BOLD-100 In COVID-19 Variants

Bold Therapeutics is pleased to be collaborating with Dr. Stephen Barr at Western University to study BOLD-100 in the COVID-19 variants of concern.
Post Photo

06-09-2020

Bold Therapeutics Receives Additional Funding to Support Development of BOLD-100 as a Novel Antiviral

Bold Therapeutics announces it is receiving additional funding of up to CAD$965,000 from NRC IRAP to support the development of BOLD-100 as a novel antiviral.
Post Photo

05-11-2021

FDA Grants Bold Therapeutics BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer

Bold Therapeutics announces that the U.S. Food & Drug Administration has granted BOLD-100 an Orphan Drug Designation in the treatment of gastric cancer.
Post Photo

04-16-2021

BOLD-100 Effective In Vitro Against COVID-19 Variants

Bold Therapeutics announces that new research completed by collaborators shows BOLD-100 consistently reduced viral concentrations in COVID-19 variants.
View All